Savara Inc Other Non-Current Liabilities
Savara Inc (SVRA) had Other Non-Current Liabilities of $770.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-11
- 2026-06-30: Other Liabilities, Noncurrent $770.00K.
- 2025-12-31: Other Liabilities, Noncurrent $0.00.
- 2025-09-30: Other Liabilities, Noncurrent $0.00.
- 2025-06-30: Other Liabilities, Noncurrent $0.00.
| Period end | Other Liabilities, Noncurrent |
|---|---|
| 2026-06-30 | $770.00K 10-Q · filed 2026-08-11 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-11 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 |
| 2025-03-31 | $44.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $87.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | $128.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $169.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $208.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $247.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $284.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $20.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $37.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $54.00K 10-K · filed 2024-03-07 |
| 2022-09-30 | $71.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $87.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $102.00K 10-Q · filed 2022-05-11 |
| 2021-12-31 | $117.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $34.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $35.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $58.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $84.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | $101.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $39.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $199.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $513.00K 10-K · filed 2021-03-10 |
| 2019-09-30 | $572.00K 10-Q · filed 2019-11-07 |
| 2018-12-31 | $70.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |